Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

R. Foster, Graham; H. Afdhal, Nezam; K. Roberts, Stuart; Bräu, Norbert; Gane, Edward; Pianko, Stephen; Lawitz, Eric; Thompson, Alexander; L. Shiffman, Mitchell; Cooper, Curtis; Towner, William; Conway, Brian; Ruane, Peter; Bourlière, Marc; Asselah, Tarik; Berg, Thomas; Zeuzem, Stefan; Rosenberg, William; Agarwal, Kosh; Stedman, Catherine; Mo, Hongmei; Dvory‐Sobol, Hadas; Han, Lingling; Wang, Jing; McNally, John; Osinusi, Anu; M. Brainard, Diana; G. McHutchison, John; Mazzotta, Francesco; T. Tran, Tram; C. Gordon, Stuart; Patel, Keyur; Reau, Nancy; Mangia, Alessandra; Sulkowski, Mark

doi:10.1056/nejmoa1512612

Public

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Published in New England Journal of Medicine • Nov 17, 2015

Authors:

Graham R. Foster

Nezam H. Afdhal

Stuart K. Roberts

Abstract

BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS: We conduct...

Subject

Medicine

Sofosbuvir

Ribavirin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!